venanprubart (LY3361237) / Eli Lilly - LARVOL DELTA

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus (clinicaltrials.gov) - P2 | N=85 | Terminated | Sponsor: Eli Lilly and Company | Completed ➔ Terminated; Study terminated due to lack of efficacy

Trial termination • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Stanford University | N=12 ➔ 0 | Trial completion date: Dec 2025 ➔ Jan 2028 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Oct 2025 ➔ Jan 2027

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Immunology • Sjogren's Syndrome

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus (clinicaltrials.gov) - P2 | N=85 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome (clinicaltrials.gov) - P2 | N=12 | Not yet recruiting | Sponsor: Stanford University

New P2 trial • Immunology • Sjogren's Syndrome

A Study of LY3361237 in Participants With Psoriasis (clinicaltrials.gov) - P1 | N=21 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed

Trial completion • Dermatology • Immunology • Psoriasis

A Study of LY3361237 in Participants With Psoriasis (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Dermatology • Immunology • Psoriasis

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Aug 2023 ➔ Apr 2024 | Trial primary completion date: Apr 2023 ➔ Jan 2024

Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus (clinicaltrials.gov) - P2; N=90; Not yet recruiting; Sponsor: Eli Lilly and Company

Clinical • New P2 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Study of LY3361237 in Participants With Psoriasis (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis

A Study of LY3361237 in Participants With Psoriasis (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Eli Lilly and Company

New P1 trial • Dermatology • Immunology • Psoriasis

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1; N=28; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed

Clinical • Trial completion • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1; N=24; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Eli Lilly and Company; Suspended ➔ Recruiting

Clinical • Enrollment open • Lupus • Systemic Lupus Erythematosus

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1; N=24; Suspended; Sponsor: Eli Lilly and Company; Trial completion date: Oct 2020 ➔ Jan 2021; Recruiting ➔ Suspended; Trial primary completion date: Oct 2020 ➔ Jan 2021

Clinical • Trial completion date • Trial primary completion date • Trial suspension • Immunology • Lupus • Systemic Lupus Erythematosus

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Eli Lilly and Company; Trial completion date: May 2020 ➔ Oct 2020; Trial primary completion date: May 2020 ➔ Oct 2020

Clinical • Trial completion date • Trial primary completion date

A Study of LY3361237 in Healthy Participants (clinicaltrials.gov) - P1; N=64; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed

Clinical • Trial completion

A Study of LY3361237 in Healthy Participants (clinicaltrials.gov) - P1; N=85; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open